Multipl Sklerozda Kök Hücre Tedavisi

Nociti V, Romozzi M, Mirabella M. Challenges in Diagnosis and Therapeutic Strategies in Late-Onset Multiple Sclerosis. J Pers Med. 2024;14(4):400. Published 2024 Apr 10. doi:10.3390/jpm14040400

Lomer NB, Asalemi KA, Saberi A, Sarlak K. Predictors of multiple sclerosis progression: A systematic review of conventional magnetic resonance imaging studies. PLoS One. 2024;19(4):e0300415. Published 2024 Apr 16. doi:10.1371/journal.pone.0300415

Guo J, Wu J, Wang L, et al. Treatment algorithms of relapsing multiple sclerosis: an exploration based on the available disease-modifying therapies in China. Ther Adv Neurol Disord. 2024;17:17562864241239117. Published 2024 Apr 13. doi:10.1177/17562864241239117

Tarantino S, Proietti Checchi M, Papetti L, Monte G, Ferilli MAN, Valeriani M. Neuropsychological performances, quality of life, and psychological issues in pediatric onset multiple sclerosis: a narrative review. Neurol Sci. 2024;45(5):1913-1930. doi:10.1007/s10072-023-07281-y

Grzegorski T, Losy J. What do we currently know about the clinically isolated syndrome suggestive of multiple sclerosis? An update. Rev Neurosci. 2020;31(3):335-349. doi:10.1515/revneuro-2019-0084

Hrušková N, Berchová Bímová K, Davies Smith A, et al. People with newly diagnosed multiple sclerosis benefit from a complex preventative intervention-a single group prospective study with follow up. Front Neurol. 2024;15:1373401. Published 2024 Apr 10. doi:10.3389/fneur.2024.1373401

Wendebourg MJ, Nagy S, Derfuss T, Parmar K, Schlaeger R. Magnetic resonance imaging in immune-mediated myelopathies. J Neurol. 2020;267(5):1233-1244. doi:10.1007/s00415-019-09206-2

Kukanja P, Langseth CM, Rubio Rodríguez-Kirby LA, et al. Cellular architecture of evolving neuroinflammatory lesions and multiple sclerosis pathology. Cell. 2024;187(8):1990-2009.e19. doi:10.1016/j.cell.2024.02.030

Boullerne AI, Goudey B, Paganini J, Erlichster M, Gaitonde S, Feinstein DL. Validation of tag SNPs for multiple sclerosis HLA risk alleles across the 1000 genomes panel. Hum Immunol. 2024;85(3):110790. doi:10.1016/j.humimm.2024.110790

Fogel A, Olcer M, Goel A, Feng X, Reder AT. Novel biomarkers and interferon signature in secondary progressive multiple sclerosis. J Neuroimmunol. 2024;389:578328. doi:10.1016/j.jneuroim.2024.578328

Canto-Gomes J, Boleixa D, Teixeira C, et al. Distinct disease-modifying therapies are associated with different blood immune cell profiles in people with relapsing-remitting multiple sclerosis [published correction appears in Int Immunopharmacol. 2024 Dec 25;143(Pt 2):113555. doi: 10.1016/j.intimp.2024.113555.]. Int Immunopharmacol. 2024;131:111826. doi:10.1016/j.intimp.2024.111826

Haschka D, Tymoszuk P, Bsteh G, et al. Expansion of Neutrophils and Classical and Nonclassical Monocytes as a Hallmark in Relapsing-Remitting Multiple Sclerosis. Front Immunol. 2020;11:594. Published 2020 Apr 29. doi:10.3389/fimmu.2020.00594

Baeyens AAL, Schwab SR. Finding a Way Out: S1P Signaling and Immune Cell Migration. Annu Rev Immunol. 2020;38:759-784. doi:10.1146/annurev-immunol-081519-083952

de Seze J, Bigaut K. Do disease-modifying drugs (DMD) have a positive impact on the occurrence of secondary progressive multiple sclerosis? Yes. Rev Neurol (Paris). 2020;176(6):497-499. doi:10.1016/j.neurol.2020.03.003

Nicholas JA, Edwards NC, Edwards RA, Dellarole A, Grosso M, Phillips AL. Real-world adherence to, and persistence with, once- and twice-daily oral disease-modifying drugs in patients with multiple sclerosis: a systematic review and meta-analysis. BMC Neurol. 2020;20(1):281. Published 2020 Jul 14. doi:10.1186/s12883-020-01830-0

Amoriello R, Greiff V, Aldinucci A, et al. The TCR Repertoire Reconstitution in Multiple Sclerosis: Comparing One-Shot and Continuous Immunosuppressive Therapies. Front Immunol. 2020;11:559. Published 2020 Apr 9. doi:10.3389/fimmu.2020.00559

Desu HL, Plastini M, Illiano P, et al. IC100: a novel anti-ASC monoclonal antibody improves functional outcomes in an animal model of multiple sclerosis. J Neuroinflammation. 2020;17(1):143. Published 2020 May 4. doi:10.1186/s12974-020-01826-0

Atkins HL, Freedman MS. Hematopoietic stem cell therapy for multiple sclerosis: top 10 lessons learned. Neurotherapeutics. 2013;10(1):68-76. doi:10.1007/s13311-012-0162-5

Das J, Gill A, Lo C, et al. A Case of Multiple Sclerosis-Like Relapsing Remitting Encephalomyelitis Following Allogeneic Hematopoietic Stem Cell Transplantation and a Review of the Published Literature. Front Immunol. 2020;11:668. Published 2020 May 5. doi:10.3389/fimmu.2020.00668

Mancardi GL, Sormani MP, Gualandi F, et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial. Neurology. 2015;84(10):981-988. doi:10.1212/WNL.0000000000001329

Hendrawan K, Khoo MLM, Visweswaran M, et al. Long-Term Suppression of Circulating Proinflammatory Cytokines in Multiple Sclerosis Patients Following Autologous Haematopoietic Stem Cell Transplantation. Front Immunol. 2022;12:782935. Published 2022 Jan 19. doi:10.3389/fimmu.2021.782935

Tsantes E, Curti E, Collura F, Bazzurri V, Fiore A, Granella F. Five- and seven-year prognostic value of new effectiveness measures (NEDA, MEDA and six-month delayed NEDA) in relapsing-remitting multiple sclerosis. J Neurol Sci. 2020;414:116827. doi:10.1016/j.jns.2020.116827

Dive D, Dauby S, Lommers E, Hansen I, Maquet P. Actualités thérapeutiques dans la sclérose en plaques [Multiple sclerosis : therapy update]. Rev Med Liege. 2020;75(5-6):382-385.

Schilke ED, Remoli G, Funelli E, et al. Current use of fluid biomarkers as outcome measures in Multiple Sclerosis (MS): a review of ongoing pharmacological clinical trials. Neurol Sci. 2024;45(5):1931-1944. doi:10.1007/s10072-023-07228-3

Strunz PP, Froehlich M, Gernert M, et al. Immunological Adverse Events After Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis Patients. Front Immunol. 2021;12:723349. Published 2021 Sep 3. doi:10.3389/fimmu.2021.723349

Strunz PP, Froehlich M, Gernert M, et al. Immunological Adverse Events After Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis Patients. Front Immunol. 2021;12:723349. Published 2021 Sep 3. doi:10.3389/fimmu.2021.723349

Shariati A, Nemati R, Sadeghipour Y, et al. Mesenchymal stromal cells (MSCs) for neurodegenerative disease: A promising frontier. Eur J Cell Biol. 2020;99(6):151097. doi:10.1016/j.ejcb.2020.151097

McIntyre LL, Greilach SA, Othy S, et al. Regulatory T cells promote remyelination in the murine experimental autoimmune encephalomyelitis model of multiple sclerosis following human neural stem cell transplant. Neurobiol Dis. 2020;140:104868. doi:10.1016/j.nbd.2020.104868

Morales Pantoja IE, Smith MD, Rajbhandari L, et al. iPSCs from people with MS can differentiate into oligodendrocytes in a homeostatic but not an inflammatory milieu. PLoS One. 2020;15(6):e0233980. Published 2020 Jun 8. doi:10.1371/journal.pone.0233980

Morales Pantoja IE, Smith MD, Rajbhandari L, et al. iPSCs from people with MS can differentiate into oligodendrocytes in a homeostatic but not an inflammatory milieu. PLoS One. 2020;15(6):e0233980. Published 2020 Jun 8. doi:10.1371/journal.pone.0233980

Lycke J, Lenhoff S. Intensive immunosuppression followed by autologous hematopoietic stem cell transplantation for the treatment of multiple sclerosis. Ther Adv Neurol Disord. 2020;13:1756286420929467. Published 2020 Jun 24. doi:10.1177/1756286420929467

Thebault S, Lee H, Bose G, et al. Neurotoxicity after hematopoietic stem cell transplant in multiple sclerosis. Ann Clin Transl Neurol. 2020;7(5):767-775. doi:10.1002/acn3.51045

Msheik A, Assi F, Hamed F, et al. Stem Cell Transplantation for Multiple Sclerosis: A 2023 Review of Published Studies. Cureus. 2023;15(10):e47972. Published 2023 Oct 30. doi:10.7759/cureus.47972

Shevchenko JL, Kuznetsov AN, Ionova TI, et al. Long-term outcomes of autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis: physician's and patient's perspectives. Ann Hematol. 2015;94(7):1149-1157. doi:10.1007/s00277-015-2337-8